207 related articles for article (PubMed ID: 30607817)
1. Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU.
Dhillon S
Clin Drug Investig; 2019 Feb; 39(2):221-229. PubMed ID: 30607817
[TBL] [Abstract][Full Text] [Related]
2. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Chia SKL; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Gokmen E; Bashford A; Ruiz Borrego M; Kim SB; Jakobsen EH; Ciceniene A; Inoue K; Overkamp F; Heijns JB; Armstrong AC; Link JS; Joy AA; Bryce R; Wong A; Moran S; Yao B; Xu F; Auerbach A; Buyse M; Chan A;
Lancet Oncol; 2017 Dec; 18(12):1688-1700. PubMed ID: 29146401
[TBL] [Abstract][Full Text] [Related]
3. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
4. U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer.
Singh H; Walker AJ; Amiri-Kordestani L; Cheng J; Tang S; Balcazar P; Barnett-Ringgold K; Palmby TR; Cao X; Zheng N; Liu Q; Yu J; Pierce WF; Daniels SR; Sridhara R; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Aug; 24(15):3486-3491. PubMed ID: 29523624
[TBL] [Abstract][Full Text] [Related]
5. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Chan A; Moy B; Mansi J; Ejlertsen B; Holmes FA; Chia S; Iwata H; Gnant M; Loibl S; Barrios CH; Somali I; Smichkoska S; Martinez N; Alonso MG; Link JS; Mayer IA; Cold S; Murillo SM; Senecal F; Inoue K; Ruiz-Borrego M; Hui R; Denduluri N; Patt D; Rugo HS; Johnston SRD; Bryce R; Zhang B; Xu F; Wong A; Martin M;
Clin Breast Cancer; 2021 Feb; 21(1):80-91.e7. PubMed ID: 33183970
[TBL] [Abstract][Full Text] [Related]
6. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.
Iwata H; Masuda N; Kim SB; Inoue K; Rai Y; Fujita T; Chiu J; Ohtani S; Takahashi M; Miyaki T; Lu YS; Xu B; Yap YS; Bustam A; Yao B; Zhang B; Bryce R; Chan A
Future Oncol; 2019 Jul; 15(21):2489-2501. PubMed ID: 31140297
[No Abstract] [Full Text] [Related]
7. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.
Delaloge S; Cella D; Ye Y; Buyse M; Chan A; Barrios CH; Holmes FA; Mansi J; Iwata H; Ejlertsen B; Moy B; Chia SKL; Gnant M; Smichkoska S; Ciceniene A; Martinez N; Filipović S; Ben-Baruch NE; Joy AA; Langkjer ST; Senecal F; de Boer RH; Moran S; Yao B; Bryce R; Auerbach A; Fallowfield L; Martin M
Ann Oncol; 2019 Apr; 30(4):567-574. PubMed ID: 30689703
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Chia SKL; Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Kim SB; Jakobsen EH; Harvey V; Robert N; Smith J; Harker G; Zhang B; Eli LD; Ye Y; Lalani AS; Buyse M; Chan A
Breast Cancer Res; 2019 Mar; 21(1):39. PubMed ID: 30867034
[TBL] [Abstract][Full Text] [Related]
9. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Holmes FA; Moy B; Delaloge S; Chia SKL; Ejlertsen B; Mansi J; Iwata H; Gnant M; Buyse M; Barrios CH; Silovski T; Šeparović R; Bashford A; Zotano AG; Denduluri N; Patt D; Gokmen E; Gore I; Smith JW; Loibl S; Masuda N; Tomašević Z; Petráková K; DiPrimeo D; Wong A; Martin M; Chan A;
Eur J Cancer; 2023 May; 184():48-59. PubMed ID: 36898233
[TBL] [Abstract][Full Text] [Related]
10. Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.
Lüftner D; Tesch H; Schmidt M; Hartkopf AD; Streicher S; Resch A; Genovese L; Rosé C; Valenti R; Harbeck N
Eur J Cancer; 2021 Jun; 150():268-277. PubMed ID: 33971386
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
Schwartz NRM; Flanagan MR; Babigumira JB; Steuten LM; Roth JA
J Manag Care Spec Pharm; 2019 Oct; 25(10):1133-1139. PubMed ID: 31556818
[TBL] [Abstract][Full Text] [Related]
13. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
Blackwell KL; Zaman K; Qin S; Tkaczuk KHR; Campone M; Hunt D; Bryce R; Goldstein LJ;
Clin Breast Cancer; 2019 Apr; 19(2):97-104.e4. PubMed ID: 30655172
[TBL] [Abstract][Full Text] [Related]
14. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.
Mortimer J; Di Palma J; Schmid K; Ye Y; Jahanzeb M
Breast Cancer Res; 2019 Feb; 21(1):32. PubMed ID: 30813966
[TBL] [Abstract][Full Text] [Related]
15. Neratinib in the early-stage/extended adjuvant breast cancer patient.
O'Shaughnessy JA; Isaacs C; O'Regan R
Clin Adv Hematol Oncol; 2020 Aug; 18 Suppl 12(8):1-20. PubMed ID: 33843843
[TBL] [Abstract][Full Text] [Related]
16. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
Tiwari SR; Mishra P; Abraham J
Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
[TBL] [Abstract][Full Text] [Related]
17. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
Barcenas CH; Hurvitz SA; Di Palma JA; Bose R; Chien AJ; Iannotti N; Marx G; Brufsky A; Litvak A; Ibrahim E; Alvarez RH; Ruiz-Borrego M; Chan N; Manalo Y; Kellum A; Trudeau M; Thirlwell M; Garcia Saenz J; Hunt D; Bryce R; McCulloch L; Rugo HS; Tripathy D; Chan A;
Ann Oncol; 2020 Sep; 31(9):1223-1230. PubMed ID: 32464281
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
[TBL] [Abstract][Full Text] [Related]
19. Neratinib for the treatment of HER2-positive early stage breast cancer.
Echavarria I; López-Tarruella S; Márquez-Rodas I; Jerez Y; Martin M
Expert Rev Anticancer Ther; 2017 Aug; 17(8):669-679. PubMed ID: 28649882
[TBL] [Abstract][Full Text] [Related]
20. Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer.
Jerez Y; Herrero B; Arregui M; Morón B; Martín M; Echavarría I
Future Oncol; 2020 Jun; 16(17):1165-1177. PubMed ID: 32458702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]